A Person Is at Risk for a Tuberculosis (TB) Infection When They Are Near a Person With Active TB: What Is Another Risk Factor?

The short answer is a weakened immune system. Close contact with someone who has active, contagious pulmonary TB is the best-known risk factor, but a person whose immune defenses are suppressed — by HIV, diabetes, certain medicines, or age — faces a sharply higher chance of progressing to TB disease after exposure. The World Health Organization estimates that roughly a quarter of the world's population carries latent TB infection, and only about 5-10% of those people ever develop active disease — so immunity, not exposure alone, largely decides who gets sick.

How Latent Infection Differs From Active TB Disease

Latent TB infection means the bacteria are alive in the body but held in check by the immune system. The person has no symptoms, cannot transmit TB to anyone, and usually tests positive on a tuberculosis blood test or skin test. Active TB disease means the bacteria are multiplying and causing illness, and in pulmonary cases the person can spread infection through coughing.

The distinction matters for your question because risk factors split into two jobs. Some factors raise the chance of being exposed and infected in the first place — close contact, crowded housing, working in a clinic or prison. Other factors raise the chance that a quiet latent infection breaks into active disease, sometimes years or decades later. A weakened immune system is the strongest factor in that second category.

The U.S. Centers for Disease Control and Prevention notes that people with untreated latent TB have roughly a 5-10% lifetime risk of developing active TB disease, with most cases appearing within the first two years after infection. That progression rate is not the same for everyone. In a person with advanced HIV and no treatment, the annual risk alone can reach around 10% — roughly ten times the lifetime risk of someone with a healthy immune system.

That gap is why public health programs treat latent TB differently depending on who carries it. A young, healthy adult with a positive skin test may be offered preventive therapy on a watchful schedule. A person with HIV, recent organ transplant, or tumor necrosis factor (TNF) inhibitor therapy is often pushed toward treatment promptly because the immune system is unlikely to keep the bacteria contained.

Why a Weak Immune System Is the Other Major Risk Factor

A weakened immune system — clinicians call it immunosuppression — removes the wall that keeps TB bacteria dormant. When the T cells that patrol for infected cells decline in number or function, the bacteria can multiply unchecked. That is why conditions that damage these defenses count as independent risk factors, separate from any contact with a sick person.

The clearest numbers come from HIV. The CDC and WHO both classify HIV infection as the strongest known risk factor for progressing from latent infection to active TB disease, and TB is the leading cause of death among people with HIV worldwide. A person living with untreated HIV who acquires TB infection is about 18 to 20 times more likely to develop active TB disease than someone without HIV, a figure the CDC has published in its TB risk guidance.

Other conditions sit on the same spectrum. Diabetes roughly doubles or triples the risk of active TB disease, according to the CDC's Division of Tuberculosis Elimination, and uncontrolled blood sugar makes the risk worse. Chronic kidney disease, especially on dialysis, raises it further, as does silicosis from occupational dust exposure. Any of these mean the immune system is working with less margin.

The treatment angle is often missed. Corticosteroid therapy at the equivalent of 15 milligrams or more of prednisone daily for a month or longer, TNF inhibitors such as infliximab or adalimumab used for rheumatoid arthritis and Crohn's disease, and chemotherapy for cancer all suppress the immune system by design. Patients on these therapies are routinely screened for latent TB before they start, precisely because the medicine can unlock the infection.

Which Medical Conditions Raise Your Risk

Two things stand out for someone reading this table on a phone at a clinic. First, transplant recipients on long-term immunosuppressants have the steepest climb of any group, because the drugs that keep a new organ alive also keep TB defenses switched off. Second, a recent infection carries a fast, concentrated risk: most active cases in otherwise healthy people happen in the first 24 months after exposure, then taper off.

A note on method. These are population-level multipliers, not individual predictions. A person with well-controlled diabetes and excellent blood sugar may track much closer to baseline than the 2-3 times figure, and a person with poorly controlled diabetes on insulin and with kidney complications may track higher. The CDC publishes these as relative risks from surveillance and cohort studies; confirm current figures on its TB risk factors page if you need a recent edition for a clinical reference.

The practical takeaway for screening is blunt: if you've been near someone with active TB and you also have any condition on this list, tell your clinician about both. Guidelines from the CDC and the American Thoracic Society recommend that immunocompromised people who are newly infected receive treatment for latent TB rather than watchful waiting, because their bodies are less likely to keep the bacteria contained.

Daily Medicines and Treatments That Suppress TB Defense

Some of the biggest immunity risks come from medicine cabinets, not infections. Clinicians who prescribe long-term corticosteroids, biologics, or cancer chemotherapy screen patients for latent TB beforehand — a routine that started as an oncology and rheumatology standard and now spreads through transplant care. The screening exists because these drugs can reactivate TB in a test-positive person within weeks of starting.

The patterns are specific. Infliximab and adalimumab, both TNF inhibitors, carry a higher reactivation risk than some newer biologics, according to labeling from their manufacturers and the FDA's boxed warnings; that label class warns about a serious risk of tuberculosis, including reactivation of latent disease. The prescribing information for methotrexate, used in rheumatoid arthritis, also lists TB as a possible complication in people who have had exposure. This is why the label warns of serious infections including reactivation of tuberculosis.

Doses matter too. The CDC's latent TB treatment guidance flags prednisone at 15 mg per day or more for at least one month as immunosuppression — the threshold used in screening algorithms. A short steroid burst for a poison ivy rash is not the same thing as six months of low-dose steroids for Crohn's disease, though both should prompt a TB conversation if a person has exposure history.

For someone reading this at home, the action step is concrete. Tell any prescriber about a positive TB skin or blood test before starting a biologic or long steroid course. If you were started on one without that conversation and you've had close contact with active TB, ask for a TB blood test (IGRA). The test is not a diagnosis of disease, and a chest X-ray and sputum tests follow if the result is positive.

Crowded Housing, Prisons, and Nursing Homes

If immune status is the strongest biological risk, confinement is the strongest environmental one. Prisons, jails, nursing homes, homeless shelters, and crowded multi-family housing all concentrate people at risk for TB in close space, so a single active case reaches more people. The CDC classifies residents and employees of correctional facilities, long-term care facilities, and homeless shelters as targeted groups for TB screening and testing.

Transmission in these settings looks different from transmission on a bus. TB spreads through the air from a coughing person, and it needs hours of shared air rather than a one-time encounter. That means the household of an active case matters most — in studies of household contacts, the CDC notes rough transmission rates of 30% or more to household members, much higher than casual contact with a stranger. A jail bunkmate has that same sustained exposure inside an enclosed room.

The risk estimate changes when crowding and immunity overlap. A prison building holding people with HIV, diabetes, and untreated latent infection together produces more active disease per exposure than a dormitory of healthy students. Public health agencies respond with routine entry screening, isolation of active cases, and treatment of latent infection for staff and inmates. The screening schedule for long-term care staff, for example, typically includes an annual TB test in regions with higher TB rates, though that varies by state and facility policy — check the local health department's current rules.

Those three regions also illustrate why the risk-factor calculation is regional. In the U.S., where total national TB incidence is low, most cases now arise from reactivation of latent infection in people born outside the country or with weakened immunity, which the CDC has reported for years. In regions with higher transmission, a prison outbreak may spread to staff and family long before anyone develops symptoms.

Age, Travel, and Occupation All Shift the Odds

Age matters at both ends of life. The CDC lists children under 5 and adults over 65 as groups at higher risk for developing active TB disease once exposed. In young children, the immune system is still maturing, and the CDC recommends closer follow-up for young children who are contacts of an active case. In older adults, waning immunity and any chronic conditions compound the risk.

Travel and residence history provide another layer. The CDC estimates that people born in countries where TB is common have a higher risk of latent infection, and screening guidance for U.S. healthcare workers includes past residence in a high-incidence country as a factor. That does not mean a person from a high-incidence country is sick — most are not — but it means the lifetime chance of having come into silent contact with TB bacteria is higher, which makes any later immune suppression more consequential.

Occupational exposure adds a steady, low-level risk. The CDC recommends TB screening for healthcare workers with direct patient contact, and for staff at homeless shelters, correctional facilities, and nursing homes. The risk also rises in labs that handle TB specimens and in settings that perform certain lung procedures. The screening requirement is usually at hire, then annually or after exposure.

The quieter factor is poverty and access to care. People without stable housing, and those without insurance or primary care, are more likely to have undiagnosed active TB, which means more opportunity to transmit. The CDC's TB screening guidance lists homelessness and healthcare access gaps among the social risk factors for TB disease, alongside conditions like HIV and diabetes. Read together, the list of risks outside close contact adds up to a simple rule: overlap a crowded environment, limited healthcare access, or a weak immune system with exposure, and the odds rise.

Two Scenarios That Show How Risk Factors Combine

Scenario one: a 28-year-old warehouse worker who shares an apartment with a cousin diagnosed with active pulmonary TB. He has a normal immune system and no conditions. His risk of active disease is meaningful but comparatively low; if a TB blood test is positive, current public health guidance is preventive therapy, which the CDC's guidelines state reduces active TB risk by roughly 60-90% depending on the regimen chosen and how closely it is completed. The concerning part in this case is the recent infection itself, since the first two years carry the biggest bite.

Scenario two: a 47-year-old woman on adalimumab for rheumatoid arthritis who works at a homeless shelter. Two independent factors — immunosuppressive therapy and an occupational setting with likely exposure — stack on top of any contact with an active case. If her TB screening was up to date before the biologic started, she and her clinician have a baseline to compare. If not, a positive test now creates a real decision point: treat latent infection, consider pausing the biologic, or both, usually with specialist input.

Neither scenario can be resolved by a single rule. The reason is that no credible source calculates a combined score. The CDC and WHO publish individual risk factors and relative risks; they do not supply a formula that multiplies them. That gap is worth knowing, because someone looking at a 2-3x diabetes multiplier plus a 30% household exposure rate might assume a simple product. The clinical approach is to treat the presence of any major risk factor as a reason to test, and then act on the test result.

For the second scenario, timing is the hard part. The standard before starting a TNF inhibitor is a baseline TB test plus a symptom review and chest X-ray when indicated, per the drug labels. If the person started without that, current practice is to test as soon as the gap is noticed and report it to the prescriber. That action, not a wait-and-see, is what the drug labels and CDC guidance support.

What to Do If You Share a Risk Factor and Exposure

The first move is a conversation with a clinician, not a search window. Call a primary care office, a local health department TB program, or the clinic that ordered the TB test. Tell them both facts — exposure and any risk factor on your list. A local TB program can test contacts of a known case at no cost in most jurisdictions, and that is often the fastest route.

The second move is to get the right test. A TB blood test (IGRA, either QuantiFERON or T-SPOT) or a tuberculin skin test (TST, the PPD) tells you whether your body has ever reacted to TB bacteria. Neither test tells you whether the infection is active. If the test is positive and you have symptoms — a cough lasting three weeks or more, night sweats, fever, unexplained weight loss, or coughing up blood — a chest X-ray and sputum tests follow. The CDC recommends prompt evaluation for anyone with those symptoms.

The third move is to know who takes priority. According to CDC latent TB treatment guidance, people with HIV, recent contact with an active case, organ transplants, prolonged corticosteroid use, and TNF inhibitor therapy are highest priority for screening and treatment of latent infection. If you fall into one of those groups, don't wait for the annual screening cycle.

The fourth move is follow-through. Latent TB treatment options have changed in recent years — the CDC's guidance includes short-course rifamycin-based regimens of 3-4 months alongside the older 6-9 month isoniazid regimen. Completion still matters more than the choice. The 60-90% reduction in active TB risk cited earlier assumes the course is finished; partial treatment narrows that protection.

One wrinkle in reading your own results: a positive TB skin test can be misleading after a BCG vaccine, which is given at birth in many countries. The CDC notes BCG can cause a false-positive skin test but generally does not interfere with the blood test. If BCG history applies to you, the IGRA is the preferred test in current U.S. guidance — that's the kind of detail worth telling your provider before testing. the chapter of "What Do If You Share a Risk Factor and Exposure" FAQ

What is another risk factor for TB besides close contact?

A weakened immune system is the leading answer, and HIV is the most powerful single cause — the CDC estimates people with untreated HIV are 18-20 times more likely to develop active TB after infection. Diabetes, chronic kidney disease, organ transplant, and long-term steroid or TNF inhibitor therapy also count. Pregnancy, young age under 5, and age over 65 are additional risk factors worth raising with a clinician.

Can a person with latent TB spread it?

No. Latent TB infection means the bacteria are inactive and staying that way, and the person has no symptoms and cannot pass TB to anyone. Only active pulmonary TB spreads through coughing. The CDC's roughly 5-10% lifetime progression figure means most people with latent infection never become infectious, but it also means silence isn't proof the infection is gone.

Is TB still a risk if I'm healthy and had a positive skin test years ago?

Yes, but the risk is small and manageable. A positive skin test without active symptoms generally means latent infection, and the CDC estimates the active-disease risk at about 5-10% over a lifetime without treatment. If you later start a biologic, high-dose steroid course, or develop diabetes, that risk rises — so mention the old positive result to every prescriber.

Can COVID-19 or flu vaccination increase TB risk?

No. TB risk comes from immune suppression, not from flu or COVID-19 vaccines. The CDC's TB risk list names medically induced immunosuppression — steroids, TNF inhibitors, cancer chemotherapy, transplant drugs — not vaccination. The one real vaccine-related wrinkle is BCG, which can cause a false-positive TB skin test but generally not a false-positive blood test.

How much does latent TB treatment reduce the risk of active TB?

Roughly 60-90%, depending on the regimen and whether the full course is completed, per CDC guidance. The short-course rifamycin options (3-4 months) and the traditional isoniazid option (6-9 months) are not identical in side-effect profile or duration; a clinician picks based on drug interactions, liver health, and adherence. Skipping doses or stopping early reduces the protection proportionally.

How often should someone with a risk factor be screened?

It depends on the risk factor and setting. Healthcare workers in the U.S. are usually tested at hire, and some facilities repeat annually or after exposure; long-term care and correctional staff follow state and facility rules. An immunocompromised person with exposure history should test as soon as exposure is known, not on a scheduled interval — the timeline to active disease is faster in that group.

What's the risk of a household member catching TB?

Much higher than casual contact. The CDC cites transmission rates of around 30% or more to household contacts of an active pulmonary case, because transmission needs sustained shared air, which a household provides. Household contacts with HIV, diabetes, or recent TB infection face the highest risk of progressing to disease and should be evaluated first.

Could a negative TB test still mean I have TB?

Yes, in a few scenarios. A newly infected person can test negative in the first 8-10 weeks before the immune response develops, and some immunocompromised people never mount a strong reaction. That is why clinicians sometimes repeat testing at a later date or combine a blood test with a chest X-ray when symptoms or exposure suggest active disease.

This article is general educational information, not a diagnosis, treatment plan, or legal or financial recommendation. Tuberculosis risk depends on individual health history, and the decision to test or treat belongs with a qualified local clinician or public health TB program. If you have symptoms like a cough lasting several weeks, night sweats, or coughing up blood, seek medical evaluation promptly; if you are in immediate danger or crisis, contact your local emergency or crisis services.